Highbridge Capital Management LLC Invests $3.44 Million in OnKure Therapeutics (NASDAQ:OKUR)

Highbridge Capital Management LLC purchased a new position in shares of OnKure Therapeutics (NASDAQ:OKUR - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 399,743 shares of the company's stock, valued at approximately $3,438,000. Highbridge Capital Management LLC owned approximately 11.96% of OnKure Therapeutics at the end of the most recent reporting period.

Wall Street Analysts Forecast Growth

Several analysts recently commented on OKUR shares. Oppenheimer reduced their price target on shares of OnKure Therapeutics from $35.00 to $30.00 and set an "outperform" rating for the company in a research report on Tuesday, March 11th. Leerink Partners assumed coverage on OnKure Therapeutics in a report on Thursday, December 5th. They set an "outperform" rating and a $33.00 price target on the stock. HC Wainwright reduced their price objective on OnKure Therapeutics from $40.00 to $34.00 and set a "buy" rating for the company in a research note on Tuesday, March 18th. Finally, Leerink Partnrs raised OnKure Therapeutics to a "strong-buy" rating in a research report on Thursday, December 5th. Three analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $32.33.

OnKure Therapeutics Trading Down 3.6 %

NASDAQ OKUR traded down $0.16 during trading hours on Tuesday, hitting $4.15. 5,917 shares of the stock were exchanged, compared to its average volume of 82,013. OnKure Therapeutics has a 12-month low of $4.15 and a 12-month high of $20.00. The stock has a 50-day moving average of $5.24. The company has a market cap of $55.69 million, a P/E ratio of -0.34 and a beta of 0.28.

Remove Ads

OnKure Therapeutics (NASDAQ:OKUR - Get Free Report) last announced its quarterly earnings data on Monday, March 10th. The company reported ($1.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.51). On average, analysts expect that OnKure Therapeutics will post -4.05 earnings per share for the current year.

OnKure Therapeutics Profile

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.